GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGUANGZHOU,China and MOSCOW, Russia ---(Businesswire)--- Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and a pipeline ofbiosimilars, today announced the companyhas reac...
GUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral...
®Under the agreement, Bio-Thera will maintain responsibilities for development, manufacturing, and supply of BAT1706. Sandoz will commercialize the medicine in all markets covered by the agreement upon regulatory approval. The license covers the US, ...
